Highlights Akeso, Inc. BOERSE MUENCHEN

Equities

4RY

KYG0146B1032

Real-time BOERSE MUENCHEN Other stock markets 15:44:10 2024-07-03 EDT			5-day change	1st Jan Change
4.46 ^EUR	+0.45%		-2.20%	-16.23%

07-01	Akeso, Inc. Announces Change of Directors	CI
06-04	Akeso Expands Territory of License Agreement for Lung Cancer Drug	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Akeso Expands Territory of License Agreement for Lung Cancer Drug	06-04	MT
Summit Therapeutics Inc. Expands License Territories for Ivonescimab	06-03	CI
Akeso's Phase 3 Trial for Non-Small Cell Lung Cancer Treatment Meets Primary Endpoint; Shares Rise 15%	05-30	MT
Akeso, Inc. Announces Registration Phase III Clinical Trial, AK112-303 (HARMONi-2) of ivonescimab (AK112, PD-1/VEGF)	05-30	CI
Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival	05-30	CI
Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut	05-24	MT
Akeso Lung Cancer Drug Gets NMPA's Marketing Approval; Stocks Crash 20%	05-24	MT
Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection	05-24	CI
National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer	04-23	CI
Akeso to Raise Over HK$1 Billion Via Share Sale	03-22	MT
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast	03-18	MT
Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18	CI
Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC	03-06	CI
Akeso Books First-Ever Profit in 2023; Shares Fall 5%	03-05	MT
Akeso, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	03-04	CI
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	02-15	RE
Akeso Unit Buys 35% Stake in Biopharmaceutical Firm from Dawnrays; Akeso Shares Slide 3%	02-08	MT
Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI	01-23	CI
Akeso, Inc. Announces Innovative Clinical Development Roadmap	01-08	CI
Chinese Medical Regulator Accepts Akeso’s Supplemental New Drug Application for Gastric Cancer Therapy	01-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Akeso, Inc. BOERSE MUENCHEN

Equities

4RY

KYG0146B1032

Highlights

Filters